Review Article

Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting

Elvira Pelosi, Germana Castelli and Ugo Testa*

Department of Hematology, Oncology and Molecular Medicine, Viale Regina Elena 299, 00161, Rome, Italy

Abstract

Isocitrate dehydrogenase (IDH) is a metabolic enzyme responsible for the enzymatic conversion of isocitrate to α-ketoglutarate (α-KG). Mutations in the IDH gene result in a novel gain-of-function, with development of neomorphic enzymatic activity determining the pathological reduction of α-KG to (R)-2-hydroxyglutarate. The accumulation of this pathological metabolite (onco-metabolite) in cancer cells is, to a large extent, responsible for the development of several cancers, including acute myeloid leukemia (AML), low-grade gliomas (LGGs) or chondrocytic tumors. Furthermore, various experimental studies have shown that IDH mutations represent an early, driver event, conserved during tumor progression in neoplasias such AML and LGG. Given all these observations, potent and selective IDH inhibitors have been developed and are currently under investigation in phase II/III clinical studies. In particular, AG-221, a first-in-class inhibitor of mutant IDH2, was tested in hematological patients with refractory/relapsing AML or myelodysplasia and showed an overall response rate of 59/159 (37%), as well as a good safety profile. Similarly, AG-120, an inhibitor of mutant IDH1, was tested in 66 relapsing/refractory AML patients and showed an overall response rate of 36%, with a complete response rate of 16%. A new IDH inhibitor, AG-811 displayed the capacity to inhibit both mutants IDH1/2 and to penetrate the blood: brain barrier, a property that would be suitable for treatment of glioma patients. On the other hand, additional observations have suggested that IDH-mutant AMLs are sensitive to treatment with BCL-2 inhibitors and to the differentiative induction with all-trans retinoic acid. In conclusion, the collective studies carried out in recent years on the characterisation of IDH-mutant tumors highlight an admirable paradigm of the virtuosic transfer from basic research (with improvements in our understanding of the physio-pathological role played by IDH mutations in the development of some tumors) to clinical studies (with the development of selective, potent and clinically-active IDH inhibitors).

Introduction

The human genome has five isocitrate dehydrogenase (IDH; EC 1.1.1.42) genes, coding for three distinct IDH enzymes, the activities of which are dependent on either nicotinamide adenine dinucleotide phosphate (NADP; NADP⁺-dependent IDH1 and IDH2) or nicotinamide adenine dinucleotide (NAD; NAD⁺-dependent IDH3). Both IDH2 and IDH3 are localized in the mitochondria and participate in the citric acid cycle for energy production, whereas IDH1 is localized in the cytoplasm and peroxisomes. IDH catalyzes the third step of the citric acid cycle, wherein NAD⁺ is converted to NADH in the mitochondria. IDH enzymes catalyze the oxidative decarboxylation of isocitrate to produce α-ketoglutarate (α-KG, also known as 2-oxoglutarate) and concomitantly produce NADPH from NADP⁺. IDH enzymes also catalyze the reductive carboxylation of α-KG to form isocitrate and concomitantly produce NADP⁺ from NADPH. IDH is dependent on NADP⁺ and on Mg²⁺.

The enzymatic reaction catalyzed by IDHs is a two-step process, in which the first step involves oxidation of isocitrate to oxaloacetate, with the second step involving decarboxylation of the carboxyl group beta to the ketone, ultimately forming α-KG (Fig. 1). The Mg²⁺ cofactor is required for the stabilization of the transi-tional states during the two-step reaction. The IDH1 and IDH2 enzymes are structurally organized as homodimers, whereas the IDH3 enzyme is organized as a heterodimer, composed by two alpha subunits, one beta subunit and one gamma subunit. The structure of IDH is composed of 14 alpha helices and 18 beta sheets. The alpha helices are located all over the structure, whereas the beta sheets (parallel and anti-parallel) are found mainly through the center of the molecule.

The crystal structure of mammalian IDH1 and IDH2 was determined and showed that each enzyme is composed of a homodimer. Each homodimer is, in turn, composed by a large domain, a clasping domain and a small domain, and contains two asymmetric and identical active sites (composed by a cleft formed by the large domain of a subunit and the small domain of the other IDH homolog). The active sites of the enzyme are accessible to substrate and cofactors; the function of the clasps is to maintain the two subunits together to form the active enzymatic site. Each IDH enzyme possesses: (a) an inactive open conformation, which is maintained through intramolecular interactions between Ser95 and Asp279 residues that serve to block access to the active site; and (b) a catalytically active closed conformation, where the Mg²⁺-isocitrate complex is able to bind between the large and small domains of the enzyme, consequent to relief of the steric impediment by Asp279 to the Mg²⁺-isocitrate complex binding.

In its active conformation, the enzyme catalyzes α-KG and NADPH production and then either remains in its active conformation

Keywords: Isocitrate dehydrogenase; Cancer; New drugs; Leukemia; Glioma.

Abbreviations: IDH, isocitrate dehydrogenase; AML, acute myeloid leukemia; alpha-KG, alpha-ketoglutarate; 2-HG, 2-Hydroxyglutarate; LGG, low-grade glioma; HGG, high-grade glioma; MDS, myelodysplastic syndrome; AITL, angioimmunoblastic T cell lymphoma; ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.

Received: 16 July 2016; Revised: 01 September 2016; Accepted: 09 September 2016

*Correspondence to: Ugo Testa, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy. Tel: 0039-649902422, Fax: 0039-649387087, E-mail: ugo.testa@iss.it

© 2016 Xia & He Publishing Inc. All rights reserved. This journal is distributed in the United States of America under DX Publisher Inc., permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The reverse cycle produces mitochondrial NADPH. Metabolites can be oxidized by IDH1 to produce cytosolic NADPH with citrate/isocitrate transported to the cytoplasm where these reactions catalyzed by IDH, malate enzyme and aldehyde dehydrogenase and methylene tetrahydrofolate dehydrogenase. Particulate systems for the generation of NADPH (Fig. 2).

The main biologic/physiologic function of IDH1/2 is related to the inhibition of α-KG-dependent dioxygenases and TCA cycle intermediates. Other studies have shown an increased sensitivity to glutaminase inhibitors and an inactivation of NADPH-dependent reactive carboxylation due to reduced glutaminase activity. Studies of metabolic flux have shown that IDH1 mutations can induce an increase in cellular metabolic flux along the TCA cycle, as well as in respiration, and can compromise the conversion of glutamine to citrate, AcCoA and fatty acids under hypoxic conditions. Importantly, cells expressing mutant IDH1 are sensitive to pharmacologic inhibition of mitochondrial oxidative metabolism. Yet, small molecules inhibiting IDH1 enzymatic activity and preventing D-2-HG accumulation fail to rescue abnormal metabolism under hypoxia. This observation suggests that a double-targeting strategy may represent an important therapeutic option, based on inhibition of both mutant enzymatic activities by using IDH inhibitors and targeting mutant IDH1-induced metabolic li-

**Fig. 1.** Enzymatic reactions catalyzed by wild-type and mutant IDH1 and IDH2. (A) Normal IDH1 and IDH2 enzymes catalyze a two-step reaction. In the first step, isocitrate is oxidized to an unstable intermediate (oxalosuccinate), with concomitant reduction of NADP⁺ to NADPH. In the second step, the oxalosuccinate loses its beta-carbonyl group, which is released as CO₂, giving rise to the formation of α-KG. The two H⁺ atoms produced during conversion of isocitrate to oxalosuccinate are used for NADP⁺ reduction to NADPH and for conversion of oxalosuccinate to α-KG. (B) Mutant IDH1 and IDH2 enzymes catalyze a reaction wherein α-KG is reduced to (R)-2-hydroxylglutarate (D-2-HG) with concomitant oxidation of NADPH to NADP⁺. From a structural point of view, α-KG and D-2-HG are very similar and differ only in replacement of the ketone group that is present in α-KG, with the hydroxyl group present in D2HG. (continuing to catalyze the isocitrate decarboxylation) or returns to its inactive conformation (restoring the Ser94-Asp279 interaction). The main biologic/physiologic function of IDH1/2 is related both to the biosynthesis of essential metabolites in the context of the tricarboxylic acid (TCA) cycle and in providing, together with the pentose phosphate pathway, one of the two essential cellular systems for the generation of NADPH (Fig. 2).

NADPH is required to maintain reduced glutathione pools and to support reductive biosynthesis. Cytosolic NADPH is mainly regenerated via the oxidative pentose phosphate pathway and in the reactions catalyzed by IDH, malate enzyme and aldehyde dehydrogenase and methylene tetrahydrofolate dehydrogenase. Particularly, for that which concerns IDHs, the reductive carboxylation of α-KG to isocitrate by IDH2 consumes mitochondrial NADPH, with citrate/isocitrate transported to the cytoplasm where these metabolites can be oxidized by IDH1 to produce cytosolic NADPH (Fig. 2). The reverse cycle produces mitochondrial NADPH.

In line with these observations, it is not surprising that lower NADPH levels have been reported in IDH1-mutant glioblastoma cells. The reaction catalyzed by IDH is one of the irreversible reactions in the TCA cycle and, therefore, needs to be carefully regulated. Thus, IDH is allosterically regulated in a positive way by adenosine diphosphate (ADP) and inhibited by adenosine triphosphate (ATP), NADPH or NADH. As such, IDH catalyzes its reaction only when ATP levels are low, while in the presence of high ATP, NADPH or NADH levels, the enzyme is inhibited, because there are existing sufficient amounts of these TCA cycle products that are available for other metabolic cycles.

In addition to TCA, glutamine-glutamate-α-KG metabolism represents an important step in the physiologic effects of IDH and is a critical pathway in IDH-mutant tumors. In this metabolic pathway, glutamine is first lysed to glutamate by the enzyme glutaminase, after which the glutamate is converted to α-KG by three different enzymes: glutamate dehydrogenase, alanine transaminase or aspartate transaminase (Fig. 2). Glutaminolysis is active in proliferating and, particularly, in tumor cells, where it represents the crucial source of nitrogen for amino acid synthesis via glutamate production and transamination. Importantly, the hypoxic microenvironment present in tumors stimulates glutamine flux into citrate for production of NADPH by IDH and for lipid production (reviewed in 5). IDH genes encode the metabolic enzymes NADP⁺-dependent isocitrate dehydrogenase, involved in the catalyzation of the oxidative decarboxylation of isocitrate to synthesize an α-KG. The two distinct IDH1 and IDH2 enzymes show a high degree of sequence similarity (about 70%) and are encoded by two distinct genes: IDH1 located on 2q33, and IDH2 located on 15q26. These genes are frequently mutated in some tumor types and represent the metabolic genes most frequently mutated in human cancers. It is reported that IDH1/2 genes are mutated in 50–80% of low-grade gliomas and secondary glioblastomas, about 20% of acute myeloid leukemia (AML), 50–60% of chondrosarcomas, about 10% of intra-hepatic cholangiocarcinoma (CCA) and 10% of melanomas. The IDH1 and IDH2 enzymes catalyze identical enzymatic reactions, but are localized to different cellular compartments, with the IDH1 enzyme localized in the cytosol and the IDH2 enzyme localized in the mitochondria. The frequency of IDH1 and IDH2 mutations are different in various tumor types; IDH1 and IDH2 mutations are almost equally frequent in AML, while IDH1 mutations are predominant in gliomas, chondrosarcomas and CCA. The mutant IDH enzymes have lost the capacity to efficiently carry out the normal oxidative reaction (i.e. conversion of isocitrate and NADP⁺ to α-KG, CO₂ and NADPH), but they have acquired a novel enzymatic function (i.e. conversion of α-KG to D-2-hydroxylglutarate (2-HG)).

In normal tissues, 2-HG is present only at very low levels. In IDH1/2-mutant tumor cells, however, it is markedly accumulated and has been shown to act as a potent oncometabolite, responsible for the induction of many of the epigenetic alterations observed in these tumor cells. The oncocgenic effects induced by 2-HG are mainly related to the inhibition of α-KG-dependent dioxygenases activity. The metabolic consequences of IDH1/2 mutations are not completely understood. However, some studies have indicated that overexpression of mutant IDH1 or IDH2 alters the levels of several metabolites, including some amino acids, glutathione metabolites and TCA cycle intermediates. Other studies have shown an increased sensitivity to glutaminase inhibitors and an inactivation of NADPH-dependent reactive carboxylation due to reduced glutaminase activity. Studies of metabolic flux have shown that IDH1 mutations can induce an increase in cellular metabolic flux along the TCA cycle, as well as in respiration, and can compromise the conversion of glutamine to citrate, AcCoA and fatty acids under hypoxic conditions. Importantly, cells expressing mutant IDH1 are sensitive to pharmacologic inhibition of mitochondrial oxidative metabolism. Yet, small molecules inhibiting IDH1 enzymatic activity and preventing D-2-HG accumulation fail to rescue abnormal metabolism under hypoxia. This observation suggests that a double-targeting strategy may represent an important therapeutic option, based on inhibition of both mutant enzymatic activities by using IDH inhibitors and targeting mutant IDH1-induced metabolic li-
abilities by drugs such as metformin or phenformin.\textsuperscript{11}

In the first section of this review, the main biologic and molecular features of the different types of IDH-mutated tumors are analyzed. In the second section, the development of anticancer therapies targeting mutant IDH enzymes is analyzed, including details of each therapy's actual development and its future perspectives.

**Main features of IDH-mutant tumors**

**IDH mutations in chondrosarcomas**

IDH1/2 (predominantly IDH1) mutations have been reported in 50–70% of central chondrosarcomas and 54% of dedifferentiated chondrosarcomas. These mutations have been found in all tumor grades of the chondrosarcomas, but have not been observed in peripheral chondrosarcomas or in soft tissue tumors.\textsuperscript{12,13} Interestingly, these mutations have also been found in enchondromas, common benign tumors of bone that can be precursors of chondrosarcomas, and very frequently also in enchondromatosis syndromes such as Ollier disease (81% of IDH1/2 mutations) and Maffucci syndrome (77% of IDH1/2 mutations), associated with DNA hypermethylation.\textsuperscript{14} These patients are at increased risk of developing highly-malignant chondrosarcomas, as well as gliomas and AMLs. These observations have suggested that the acquisition of IDH1/2 mutations is an early event of chondrosarcoma development and may represent a driver event for tumor development. Such a theory is supported by the following two observations: (a) expression of mutant IDH is sufficient to induce benign enchondromas in mouse models, and (b) additional mutations accumulate in chondrosarcomas (such as p16/CDKN2A loss), compared to enchondromas, and, in cooperation with IDH1/2 mutations are required for malignant tumor development.\textsuperscript{15,16}

In enchondromatosis syndromes, enchondromas progress to chondrosarcomas in up to 30% of cases. Furthermore, in these syndromes, there is a tendency to develop various types of tumors, including gliomas. Comparison of gliomas developed in enchondromatosis syndromes to those of sporadic IDH-mutated gliomas showed that the former were diagnosed at an earlier age, were more frequently multicentric and were more frequently located within the brainstem than sporadic IDH-mutated gliomas.\textsuperscript{17} At the molecular level, enchondromatosis gliomas were characterized by IDH mutations, but, in contrast to the sporadic IDH-mutated gliomas, do not harbor the 19/19q co-deletion.\textsuperscript{17} IDH1/2 genes were mutated in about 7% of Ewing sarcoma family tumors.\textsuperscript{18} A recent study provided evidence that mutant IDH1-R132C was able to promote chondrogenic differentiation and to inhibit osteogenic differentiation of normal mesenchymal stem cells.\textsuperscript{19} The frequent presence of mutant IDH in chondrocytic tumors offers a potential therapeutic target, by which enzymatic function can be inhibited with specific small molecule inhibitors. The effect of these inhibitors was tested on chondrosarcoma cell lines and showed an inhibitory effect on cell proliferation, cell survival and cell migration.\textsuperscript{20}
IDH mutations in bone tumors

Giant cell tumors (GCTB) are benign but locally-destructive tumors, and include the osteoclast-type multinuclear giant cells. A recent study reported a very high frequency (80%) of IDH2-R172S mutations in GCTB. Furthermore, the IDH2-R172S mutation was reportedly observed in 25% of osteosarcoma patients.

IDH mutations in gliomas

Studies carried out over the last 10 years have shown the frequent occurrence of IDH mutations in gliomas. IDH mutations are very frequently (~80%) observed in low-grade and secondary glioblastomas, but in <10% of primary glioblastomas (Table 1). Particularly, IDH1 mutations were reported to occur in 70–80% of grade II-III astrocytomas, oligodendrogliomas and oligoastrocytomas, while only a small group (3–5%) of these tumors were found to display IDH2 mutations, with the IDH1/2 mutations being mutually exclusive. It is, therefore, evident that according to the IDH mutation status, IDH1 mutations have been detected exclusively in low-grade and secondary glioblastomas. In contrast, primary glioblastomas have very low mutation rates for IDH1 or IDH2. Finally, a small percentage of grade II gliomas do not have genetic alterations in IDH1 or functional mutation in TP53.

Evidence has been provided to support the notion that secondary glioblastomas lacking IDH1 mutations develop (through a tumor progression process) from an anaplastic glioma (grade III); whereas, the majority of secondary glioblastomas displaying IDH1 mutations appear to develop (through progression) from a World Health Organization (WHO) grade II glioma. Given this peculiar stratification between primary and secondary glioblastomas, the presence of IDH mutations represent a valuable tool for distinguishing these two conditions. Furthermore, this conclusion is also supported by findings from molecular analyses, showing that primary glioblastomas exhibiting IDH mutations have a mutational profile similar to that typically displayed by secondary glioblastomas, thus supporting the hypothesis that primary glioblastomas with IDH mutations originate from pre-existing precursor lesions that were not diagnosed at the time of their occurrence and were therefore misclassified as primary.

Various other studies have shown that IDH mutations are an early event in gliomagenesis, occurring before other genetic abnormalities such as TP53 mutations, loss of 1p/19q, and copy number changes in EGFR and PTEN genes. Mouse model studies using IDH1 mutant xenografts have provided evidence to support that expression of the mutant IDH1 protein is required to sustain glioma cell growth and that pharmacological inhibition of mutant IDH1 with the IDH1-R132H inhibitor results in xenograft growth inhibition.

Importantly, mutations in IDH1/2 genes define a subset of human gliomas with a hypermethylation phenotype (G-CIMP), that provide a favorable outcome; in contrast, the absence of IDH1/2 mutations identifies a subgroup of low-grade gliomas characterized by poor prognosis. Although IDH mutant status is associated with better survival, all IDH mutant/O6-methylguanine-methyltransferase (MGMT) methylation subsets have consistently displayed higher risk of malignant transformation than of death, compared to IDH-wild type (WT) low-grade gliomas. Recent studies have suggested the classification of gliomas into IDH-WT cases, IDH-mutant group with co-deletion of chromosome arms 1p and 19q (IDH mutant-codel) and IDH-mutant group without co-deletion (IDH mutant-non-codel). A very recent study based on a very large set of gliomas indicated the existence of three types of IDH-mutated gliomas: (a) the Codel group, consisting of IDH-mutant-codel low-grade gliomas; (b) the G-CIMP-low group, including IDH-mutant-non-codel gliomas (both LGGs and glioblastomas) and manifesting a lower degree of DNA methylation; (c) the c-CIMP-high group, including IDH mutant-non-codel gliomas (both LGGs and glioblastomas) and with higher levels of DNA methylation. The G-CIMP-low group reportedly has a worse survival than the c-CIMP-high and codel groups.

Paired analysis of tumor samples from a large number of glioma patients—comparing higher-grade, progressed samples to their normal counterparts—provided further support for the IDH1/2 mutation hypothesis. A recent study of 55 low-grade gliomas revealed the presence of IDH1 mutations in 70% of tumors (7 of 10 IDH1-mutant gliomas were IDH1-R132H). This suggests that the IDH1/2 mutation hypothesis is a valid tool for distinguishing primary and secondary gliomas.

Table 1. Most frequent IDH1 and IDH2 mutations observed in human cancers

<table>
<thead>
<tr>
<th>Tumor</th>
<th>IDH1 Mutation (%)</th>
<th>IDH2 Mutation (%)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukemia</td>
<td>7–9 (R132H 50%)</td>
<td>14–18 (R140Q 60%)</td>
<td>Mardis et al, 2009 [46]; Marcucci et al, 2010 [49]; Paschka et al, 2010 [48]</td>
</tr>
<tr>
<td>Astrocytomas diffuse and anaplastic (grade II/III)</td>
<td>64–72 (R132H 90%)</td>
<td>1–5 (R172K)</td>
<td>Wang et al, 1999 [23]; Hartmann et al, 1999 [25]</td>
</tr>
<tr>
<td>Oligodendroglioma (grade II/III)</td>
<td>70–82</td>
<td>5–6</td>
<td></td>
</tr>
<tr>
<td>Oligoastrocytoma (grade II/III)</td>
<td>66–81</td>
<td>1–6</td>
<td></td>
</tr>
<tr>
<td>Secondary glioblastoma (grade IV)</td>
<td>85</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Primary glioblastoma (grade IV)</td>
<td>5–8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myelodysplastic syndromes</td>
<td>1–2 (R132)</td>
<td>8–10 (R140)</td>
<td>Patnaik et al, 2012 [78]; DiNardo et al, 2016 [80]</td>
</tr>
<tr>
<td>Angioimmunoblastic T lymphomas</td>
<td>0</td>
<td>20 (R172)</td>
<td>Cairns et al, 2012 [87]; Odejide et al, 2014 [88]; Wang et al, 2015 [89]</td>
</tr>
</tbody>
</table>

The most frequent amino acid substitutions are indicated and their frequencies at the level of IDH1- or IDH2-mutated patients are reported for acute myeloid leukemias and gliomas.
lower-grade counterparts—allowed for an integrated genomic characterization of IDH1-mutant glioma malignant progression. Various oncogenic pathways were shown to drive progression; these included, activation of the MYC and RTK-RAS-PI3K pathways and up-regulation of FOXM1 and E2F2, as well as epigenetic silencing of developmental transcription factors bound by PRC2. These findings suggest that IDH mutations are early events in gliomagenesis and cooperate with other more tardive genetic alterations to promote glioma progression.

As stated above, IDH1 mutations have been observed in <10% of glioblastomas. Glioblastoma patients with IDH1 mutations are younger and associated with a longer survival than those without IDH1 mutations. However, in patients with recurrent glioblastomas, the presence of IDH1 mutations is not predictive of progression-free survival (PFS) or radiological response. In contrast to the IDH-mutant LGGs, the IDH-WT LGGs represent a very heterogeneous group of gliomas, with various imaging and molecular characteristics at the level of genetic abnormalities and expression profiles. Although these tumors have better PFS and overall survival rates than glioblastomas, their outcomes and clinical presentations are highly variable. These observations are in line with previous studies showing that some patients with low-grade gliomas display molecular features of primary glioblastomas, such as EGFR alterations and loss of the CDKN2A locus, both of which are mutually exclusive of IDH mutations.

The oncogenic mechanism of mutant IDH in glioma cells involves production of the onco-metabolite 2-HG, which interferes with iron-dependent hydroxylases pertaining to the TET family. The presence of 2-HG levels was elevated in the urine of patients with IDH-mutant and compared with that in patients with IDH-WT glioma, the levels were found to be affected by the histopathologic grade nor genetic subtype presence of a canonical or noncanonical IDH mutation. Furthermore, in vitro and in vivo studies have shown that, in human gliomas, the IDH2 mutation leads to greater production of 2-HG than does the IDH1 mutation.

The presence of IDH1/2 mutations in gliomas has a prognostic impact: particularly, glioma patients with IDH-mutant tumors and low/normal Ki67 values have a significantly better prognosis than patients with IDH-WT gliomas showing high Ki67 labeling. A large portion of IDH-mutant gliomas display ATRX nuclear loss (about 90% of astrocytomas with ATRX nuclear loss display IDH1/2 mutations and have an astrocytic morphology and a younger age of onset); in contrast, IDH-mutant gliomas with ATRX retention are strongly associated with loss of heterozygosity at 1p/19q and oligodendroglioma cell morphology. According to IDH mutation status, 1p19q codeletion and ATRX-loss grade II gliomas can be subdivided into the following groups: IDH1mut-codel (43%), IDH1mut-codel-ATRX loss (39%), IDH1mut-noncodel-ATRXwt (6%), and IDH1wt. The median survival was much better for the IDH1mut-codel than for the other three groups. Moreover, IDH-mutant gliomas are more likely to recur locally and within the radiation field than are IDH-WT tumors, which have a greater tendency toward recurrence distant from the original site of tumor development. Finally, studies carried out in the last few years have shown that grade II and III astrocytomas with IDH mutation have an improved survival, with maximal success rates for surgical resection, and are able to predict response to temozolomide; furthermore, the IDH-mutant glioblastomas were shown to display an increased response to concurrent radiotherapy and temozolomide treatment.

The oncogenic mechanism of 2-HG in glioma cells is related not only to DNA hypermethylation but also to additional biochemical mechanisms. Lin and colleagues recently showed that R-2-HG induces hypersuccinylation in glioma cells; in fact, this onco-metabolite, through competitive inhibition of the enzyme succinate dehydrogenase, was shown to cause accumulation of the succinyl-CoA metabolite and hypersuccinylation at the level of mitochondria. In turn, the hypersuccinylation was responsible for respiratory inhibition, mitochondrial depolarization and development of a cancer metabolic phenotype. The development of mitochondrial dysfunction induced accumulation of BCL-2 anti-apoptotic protein, with consequent resistance of tumor cells to apoptotic stimuli. The hypersuccinylation contributes to IDH-mediated gliomagenesis, as supported by the experimental evidence showing that relief of the hypersuccinylation condition (either by overexpressing a desuccinylase or by glycine supplementation) reversed BCL-2 accumulation and exerted an inhibitory effect on tumor growth.

The possibility of a link between succinylation and IDH2 was also supported by a recent study showing that when the deacetylase Sirtuin 5 (an NAD+-dependent mitochondrial deacetylase) was induced by oxidative stress the desuccinylation of IDH2 was promoted, and, through this mechanism, activated the enzyme, as well as G6PD by deacetylation, thereby maintaining NADPH levels and redox balance to protect the cells against oxidative damage.

**IDH mutations in myeloid neoplasia**

IDH mutations in AML

AML is a heterogeneous hematologic malignancy, characterized by the accumulation of various somatic genetic abnormalities and of immature myeloid cells arrested at various stages of maturation. Studies carried out in the last 2 decades have led to the identification of two broad types of genetic mutations, which cooperate to support development of the leukemic process. The class I mutations confer a survival/growth advantage to hematopoietic stem cells (HSCs) and progenitor cells (HPCs), such as the mutations in NRAS or KRAS, the loss of NFI or the mutations in FLT3 receptor tyrosine kinase. The class II mutations promote self-renewal and block the differentiation of HPCs, such as the t(8:21) fusion involving AML1-ETO or the t(15;17) fusion involving PML-RARα.

In 2009, Mardis and colleagues reported frequent occurrence of IDH1/2 gene mutations occurring in AMLs, a finding that was later confirmed by the Genome Atlas Research Network. These studies and others have provided evidence that IDH1/2 mutations occur in about 20% of AML patients, including 6–16% IDH1 mutations and 8–19% IDH2 mutations (Table 1). Many studies have reported the main features of IDH-mutated AMLs, providing evidence that these AMLs are characterized by a preferential occurrence in older patients, a preferential normal cytogenetic profile or other intermediate-risk cytogenetics, an increased percentage of leukemic blasts in the bone marrow and peripheral blood at diagnosis, a more frequent association with NPM1 and FLT3 mutations, a frequent association with DNMT3A mutation, and mutual exclusivity with TET2 and WT1 mutations.
Pelosi E. et al: Isoctrate Dehydrogenase Mutations in Human Cancers

It is important to note that IDH1/2 mutations, together with DNMT3A and TET2 gene mutations, contribute to an overall occurrence in AMLs of \(>40\%\) of the mutations in genes involved in the regulation of methylation of genomic DNA.\(^5\) Analyses of the prognostic impact of IDH mutations in AMLs emerged as a matter of great controversy, with contrasting evidence either supporting a positive, a negative or a neutral impact on AML prognosis (reviewed in 4).\(^4\) However, a recent study based on a large set of AML patients provided clear evidence that overall survival for IDH-WT AMLs and IDH-mutated AMLs is comparable.\(^3\)

The large majority of leukemia-associated IDH1 and IDH2 mutations occur at the level of arginine residues present in the catalytic pocket of the enzyme, with the IDH1 mutations occurring mostly at arginine 132 (R132H or R132C or R132L or R132S or R132G) and those of IDH2 occurring mostly at arginine 172 or 140. These mutations confer to the mutant IDH1 or IDH2 protein a novel oncogenic enzymatic activity that is related to their capacity for allowing production of the R(-) enantiomer of the metabolite R-2-HG, which accumulates in IDH-mutant AMLs.\(^4\) It was suggested that R-2-HG could represent the oncogenic mediator of IDH mutants in the leukemogenic process. R-2-HG is a cofactor of many of the deoxyngeases involved in the regulation of various key biologic processes, including nucleic acid repair, hypoxic response, chromatin modification and fatty acid metabolism, while 2-HG acts as an inhibitor of these deoxyngeases.\(^5\),\(^6\) According to these findings, however, the leukemogenetic role of R-2-HG remains unclear.\(^7\)

It also remains to be demonstrated whether onco-metabolites such as R-2-HG play a causative role in leukemogenesis or, rather, are only simple biomarkers of oncogenic IDH mutants. However, a recent study using two mouse leukemic models and a patient-derived AML xenotransplantation model showed that R-2-HG, but not α-KG, is an onco-metabolite capable of inducing hyperleukocytosis and accelerating the onset of murine and human leukemias in vivo.\(^8\) Other studies have provided evidence to strongly support the role of serum 2-HG levels at diagnosis as a biomarker of IDH1/2-mutant AMLs; furthermore, the prognostic value of 2-HG levels post-induction have been shown in IDH1/2-mutant patients.\(^9\),\(^10\) Finally, a recent study carried out in 84 IDH-mutant AML patients showed that D-2-HG serum levels in IDH1-mutant, but not in IDH2-mutant patients, have a prognostic impact on outcome; this difference could be tentatively related to the different subcellular localizations of IDH1 and IDH2 enzymes.\(^11\)

An increasing number of studies have provided evidence that IDH mutants exert their pro-oncogenic effect by interfering with the differentiation program of hematopoietic cells. Thus, in 2001, Figueras and colleagues analyzed the effects on stable expression of either an IDH1 or IDH2 mutant allele on hematopoietic cell differentiation in the 32D cultured mouse cells or in primary mouse bone marrow cells; in both of these cellular systems, the expression of an IDH-mutant enzyme induced an increase in stem cell markers and impaired myeloid cell differentiation.\(^12\) Sasaki and colleagues reported the characterization of a conditional knock-in mouse model, in which the IDH1-R132H mutation was inserted into the murine IDH1 locus and expressed in all hematopoietic cells or specifically in cells of the myeloid lineage.\(^13\) These mutant mice displayed an increased number of early hematopoietic progenitors, impaired myeloid cell differentiation, anemia, spleenomegaly and extramedullary hematopoiesis.\(^14\) The hematopoietic cells of these animals displayed hypermethylated histones and changes to DNA methylation that were similar to those observed in IDH-mutant AMLs.\(^15\) A third set of experiments provided evidence that enforced expression of an IDH-mutant enzyme in or exogenous administration of a soluble form of R-2-HG to the TF-1 human erythroleukemic cells promoted cytokine independence and blocked cell differentiation.\(^16\)

Recent studies have helped to better define how IDH-mutant alleles affect hematopoietic cell differentiation in human leukemic cells. Particularly, several studies have shown that IDH-mutants affect the expression of some genes involved in retinoic metabolism and/or signaling. Interestingly, for the four cancers in which IDH mutations are frequently observed, the RAR activation pathway is targeted by IDH-mutants, as shown by two lines of evidence. In the first, RBP1, a downstream target of RAR, was recently shown to become hypermethylated following expression of mutant-IDH1 gene in cell lines, and hypermethylation of the RBP1 gene promoter was shown to be associated with down-regulation of RBP1 expression in tumor cells.\(^17\),\(^18\) In the second, the RAR activation pathway was found to be affected in all tumor types associated with frequent IDH mutations (i.e. AML, LGG, chondrosarcoma and CCA), and the process was shown to involve two genes in AML, 17 genes in LGG, 14 genes in chondrosarcoma and 5 genes in CCA.

A recent study by Boutzen and colleagues provided fundamen- tal data towards understanding how IDH-mutants affect the differentiation program of hematopoietic cells.\(^19\) In fact, gene expression studies carried out on leukemic cells bearing mutant IDH enzymes have clearly shown that IDH1-R132H mutation primes leukemic blasts to granulomonocytic differentiation (as directly supported by the finding of an enrichment of key transcriptional factors regulating myelopoiesis, such as CEBPa, PU.1, RUNX1, CEBPβ, CEBPε).\(^20\) Particularly, analysis at the level of the CEBPα gene showed that IDH1-mutant AML cells have an increased occupancy of the promoter of this gene by H3K4me3, which is associated with expression of CEBPα and of its target genes.\(^21\) Furthermore, the gene expression analysis also showed that the IDH1-R132H gene signature is particularly enriched in genes that are responsive to treatment with retinoic acid receptor (RAR) ligands, such as all-trans retinoic acid (ATRA).\(^22\) Importantly, in vitro treatment of IDH-mutant AML cells with ATRA resulted in induction of granulo-monocytic differentiation, associated with a reduction in cell viability that occurred through induction of apoptosis.\(^23\) In vivo ATRA treatment of immunodeficient mice grafted with human IDH-mutant AML cells resulted in a clear reduction of tumor burden.\(^24\) Therefore, these observations were of fundamental importance, not only for their implications at the basic research level that improved the overall understanding of the mechanism underlying the perturbation of hematopoietic cell differentiation that is elicited by IDH mutants, but also because they open new perspectives in the treatment of these leukemias.\(^25\)

The inhibitory effect of mutant IDH enzymes on hematopoietic cell differentiation is also directly supported by the observation that AGI-6780, a potent IDH2-mutant inhibitor induces the granulo-monocytic differentiation of IDH2-mutant primary AML blasts in vitro.\(^26\) These observations, to some extent, are reminiscent of the effect of ATRA on acute promyelocytic leukemia cells, demonstrating that the inhibition of mutant IDH2 can relieve a blockade in differentiation that is present in this leukemia subtype.\(^27\)

Other studies have suggested that IDH mutation can act through an inhibition of TET2 effects on DNA methylation. In fact, Figueroa et al showed that IDH1/2 mutations are mutually exclusive from TET2 mutations and inhibited the DNA demethylation activity of TET2; furthermore, IDH-mutant and TET2-mutant AMLs displayed overlapping hypermethylation signatures.\(^28\) However, remarkable differences exist between IDH1- and TET2-mutant-induced myeloid leukemias. In contrast to TET2-knockout mice, transgenic mice expressing mutant IDH1 showed reduced numbers of HSCs; this effect could be related to a down-regulation of
the DNA damage sensor ATM by alteration of histone methylation, with consequent impaired DNA repair, increased sensitivity to DNA damage and reduced self-renewal of HSCs, independent of TET2.69

Development of animal models has been of fundamental importance to the collective efforts of researchers to define the leukemogenetic role of mutant IDH enzymes. Basically, the retrospective transduction of IDH mutations, in combination with additional oncogenes, into primary bone marrow mouse cells and followed by transplantation has been shown to drive leukemia development.70,71 Other studies have provided an answer to the fundamental question of whether or not IDH1/2-mutants are required for leukemia maintenance in vivo. To answer this question, Kats and colleagues developed a mouse transgenic model of IDH2-R140Q leukemia maintenance in vivo.72 Ogawara and colleagues developed a peculiar model of IDH-dependent leukemia, in which mice were transplanted with NPM1+/− hematopoietic stem/progenitor cells co-transduced with four mutant genes (NPMc, IDH2-R140Q, DNMT3A-R882H, and FLT3ITD).73 The resultant leukemias that developed in these animals were dependent upon the expression of mutant IDH, as supported by the observation that conditional deletion of IDH2-R140Q blocked 2-HG production and maintenance of leukemic stem cells, resulting in survival of the AML mice.73 These observations strongly support the idea of therapeutic targeting of IDH in IDH1/2-mutant AMLs.

Fig. 3. Schematic model for the acquisition of IDH1/2 mutations during leukemic development. The acquisition of mutations of IDH1/2 (or in other landscaping genes affecting DNA methylation or chromatin modification) at the level of normal HSCs determines the expansion of these cells and a blockade of their differentiation, with the development of the so-called pre-leukemic stem cells (Pre-LSCs). The occurrence of additional mutational genetic events (such as FLT3 mutations) in these cells determines the formation of a fully-active leukemic process.

Studies carried out in the last few years have provided evidence that the development of a clinically-relevant leukemic disease implies a process of clonal evolution, starting from pre-leukemic clones that contain only some of the genetic alterations observed at the level of leukemic cells (Fig. 3). Importantly, pre-leukemic early genetic alterations would be present in all leukemic cells, whereas mutations present in leukemic subclones would represent mutations acquired at a later time during the leukemic development (Fig. 3). Therefore, leukemic therapies aiming to eradicate leukemic cells must target markers/events/genetic abnormalities present in all leukemic cells and, thus, which had developed as early events. The findings from parallel sequencing studies of selected AML patients have provided support for the view that IDH mutations represent an early event during leukemia development.75 It is of interest to note that pre-leukemic stem cells preferentially display mutations in “landscaping” genes that are involved in DNA methylation and chromatin modification, such as IDH1, IDH2, IK2F1, and DNMT3A.76,77

IDH mutations in myelodysplastic syndromes (MDSs)

IDH mutations are relatively frequent in MDSs. Patnaik and colleagues reported IDH1/2 mutations in 12% of patients with MDSs, with the IDH2 mutations being much more frequent than the IDH1 mutations.78 Mutational frequency was reported as 4% in patients with refractory anemia with ring sideroblasts, 12% in patients with refractory cytopenia with multilineage dysplasia, 14% in patients with refractory anemia with excess blasts (RAEB) type 1 and 23% in patients with RAEB type 2.74 Two other studies reported frequencies of IDH1/2 mutations in MDS in the order of 5–6%.79,80 In one of these two studies, the occurrence of IDH mutations in the MDS patients was found to be associated with older age, higher platelet counts and mutations in DNMT3A, ASXL1 and SRSF2; moreover, in the studied patients, the presence of IDH2 mutations was associated with a poor prognosis (reduced survival).79 In the second study, it was shown that IDH1/2 mutations occurred more frequently in patients with diploid and other intermediate-risk cytogenetics and RAEB classification by WHO, and were more frequent in patients with TP53, RUNX1, ASXL1 or TET2 mutations.80 Finally, it was reported that, at the time of leukemic transformation, 11.2% of MDS patients present with an IDH1/2 mutation.78 Lin and colleagues explored the occurrence of Tet2 and ID-1/2 mutations in MDSs at diagnosis and at the time of leukemic trans-
formation, and reached the conclusion that these mutations were maintained during disease progression. Moreover, the Tet2, but not the IDH1/2, mutations were found to affect the time of progression to leukemic transformation.81

**IDH mutations in myeloproliferative neoplasms**

IDH mutations have been intensively explored in myeloproliferative neoplasms (MPNs). In an initial study carried out on a very large population of MPN patients, a low incidence of IDH1/2 mutations (about 2%) was observed during the chronic phase. Among the various MPNs, the highest incidence of IDH1/2 mutations was observed in myelofibrosis (PMF; 4%), while this incidence was low in polycythemia vera (2%) and in essential thrombocytopenia (0.8%). Subsequent studies have confirmed that IDH mutations in primary myelofibrosis are predictive of leukemic transformation and shortened survival.83,84 Bleeding complications and rate of death were significantly higher in IDH-mutated PMF patients, compared to IDH-WT patients.85

It is important to note that, while IDH1/2 mutations are thought to represent early driver events in leukemogenesis (with stability over time), these mutations are acquired at the time of leukemic transformation in some patients with MPNs.

**IDH1/2 mutations in T cell lymphomas**

In 2012, Cairns and colleagues reported for the first time the frequent occurrence (about 20%) of IDH2 mutations in angioimmunoblastic T cell lymphomas (AITLs) (Table 1).86 In the majority of these patients, the IDH2 mutation represented the R172 subtype, and, much more rarely, the R140 subtype. Interestingly, other T cell lymphomas, such as peripheral T cell lymphomas, anaplastic large cell lymphoma, enteropathy type T cell lymphoma, cutaneous T cell lymphoma, hepatosplenic T cell lymphoma and extranodal NK/T-cell lymphoma, showed negativity for IDH mutations. Similarly, no IDH mutations were detected in Hodgkin’s lymphoma and non-Hodgkin’s B cell lymphoma.86

The above findings were confirmed in more recent studies on genetic abnormalities of AITLs and the association of IDH2 mutations with other recurrent mutations was clearly defined. Thus, Sakata-Yanagimoto performed a detailed analysis of genetic alterations occurring in AITLs and showed that three genetic mutations are frequent and occur at the level of RHOA, TET2 and DNMT3A, in addition to IDH2, and that IDH2-mutated AITLs were constantly associated with RHOA and TET2 mutations (while there was no association found between IDH2 and DNMT3A mutations).87 Odejide and colleagues basically confirmed these findings showing that, in the majority of AITL patients, IDH2 mutations co-occurred with TET2 mutations.88 Therefore, the co-occurrence of IDH2 and TET2 mutations observed in AITLs sharply contrasts with the mutually exclusive nature of TET2 and IDH1/2 alterations observed in AMLs.

**IDH2R172 mutations define a subset of patients with AITL characterized by hypermethylation of genes involved in T cell receptor signaling and T cell differentiation, with consequent down-regulation of genes associated with T cell differentiation that contributes to lymphomagenesis in this disease.**89 IDH2R172 mutations have been observed in about 33% of AITL patients, with 68% of these patients reportedly also displaying TET2 mutations and about 40% also displaying DNMT3A or RHOA mutations. Interestingly, TET2 mutations are very frequent (about 80%) in AITL, and the group of TET2-mut/IDH2-WT patients did not show the gene expression signature observed in IDH-mutated AITLs.80 Ectopic expression of IDH2R172K in CD4+ T cells was shown to lead to markedly increased levels of 2-HG, histone-3 lysine methylation and 5′-methylcytosine, and decreased 5′-hydroxymethylcytosine.90

**IDH1/2 mutations in CCA**

CCAs comprise malignancies arising from the intrahepatic (ICC), perihilar and distal biliary tree (ECC). The ICC type is the second most common primary hepatic malignancy, after hepatocellular carcinoma, and accounts for 10–20% of primary liver cancers. Studies carried out in the last few years have shown that IDH mutations are frequent in CCAs. Particularly, IDH mutations have been observed in 16–36% of ICCs and much more rarely (0–7%) in ECCs, and may be associated with clear cell or scarcely differentiated histology (Table 1).90–91 A recent whole genome sequencing analysis provided evidence that the frequencies of IDH mutations, as well as of KRAS mutants, are clearly higher among ICC patient who are hepatitis-negative.92

The prognostic significance of IDH mutations in CCA remains unclear. A study of 326 patients with resected ICC conducted by Wand et al showed that IDH mutations were associated with a better prognosis (longer survival).92 Moreover, the IDH-mutated patients in that study showed enhanced p53 expression and DNA hypermethylation.92 In contrast, another study carried out in 104 patients with advanced ICCs, no correlation was found between IDH mutations and disease outcome.93 Finally, Hayoshi and colleagues provided evidence that IDH mutations in ICC are selectively associated with a clinicopathologic subtype (type II) characterized by low mucin production and positivity for N-cadherin and NCAM.95

Interestingly, a recent study showed that IDH blocks liver progenitors from undergoing hepatocyte differentiation via promoted production of 2-HG and suppression of HNF-4α, a master transcription factor that regulates hepatocyte identity.96 In line with this observation, the study also examined genetically engineered mice expressing mutant IDH in the adult liver and found an aberrant response to hepatic injury, which was characterized by HNF-4α silencing, blocked hepatocyte differentiation and remarkably increased levels of liver cell proliferation.96 Furthermore, IDH and KRas mutations, genetic alterations co-existing in a subset of ICC patients, were shown to cooperate to drive the expansion of liver progenitor cells and their malignant transformation.96

It is important to note that, clinically, ICC shows an aggressive behavior, with poor prognosis, and no standard treatment is available other than surgical resection. Therefore, the identification of therapeutic targets for ICC is of fundamental importance. In this context, the results of a recent study by Saha and colleagues are particularly interesting; the authors reported the identification of a peculiar sensitivity of IDH-mutated tumors to the multikinase inhibitor Dasatinib, displaying a marked induction of apoptosis in ICC cancer cell lines upon treatment.97 Molecular studies have identified SRC as a critical Dasatinib target in the IDH-mutant ICC, thus suggesting that these tumor cells have a unique dependency on SRC.97

**IDH inhibitors**

Many molecules capable of targeting mutant IDH1/2 enzymes have been reported in the recent years. Some of these have been investigated in various in vitro and in vivo preclinical models, and
a few are currently under evaluation in phase I/II clinical studies focusing on the different neoplastic pathologies in which the IDH1/2 enzymes are mutated (Fig. 4). A high-throughput screening allowed the identification of a first series of potent inhibitors of IDH1-mutants; this series consists of a phenyl-glycine scaffold with one stereocenter.98 In these compounds, one enantiomer was found to be predominantly responsible for the activity of the racemic mixture. These inhibitors were characterized for their selective inhibitory activity against mutant IDH1 compared to IDH1-WT and for their capacity to markedly reduce 2-HG levels in the U87 MG glioma cell line.98 Some of these compounds were investigated only at the experimental level; for example, AGI-5198, an IDH1-mutant inhibitor, which was investigated for its properties to inhibit IDH1-mutant glioma by reducing 2-HG levels and inducing cell differentiation, or HMS-101, an IDH1-mutant inhibitor capable of inducing the apoptosis of primary IDH1-mutant AMLs and of reducing 2-HG levels.21,54 Another member of the phenyl-glycine series is ML309, an IDH1-mutant inhibitor, selective for mutant IDH1 and sparing IDH1-WT (Fig. 4). This inhibitor binds competitively to mutant IDH1 and acts as a reversible inhibitor in competition with α-KG, and not in competition with NADPH.99 The compound inhibits 2-HG production in glioma cells, with an IC₅₀=250 nM, and had displayed minimal in vivo toxicity.99

A number of studies have investigated the structural and mechanistic aspects of IDH inhibition by the various IDH inhibitors. Kinetic and structural studies have suggested that the inhibitors could be divided into two categories: (a) those able to bind to the α-KG/isocitrate site and then act as binding competitors; (b) those able to bind allosterically to the interface between the two promoters of the IDH enzyme molecule dimer. It is evident that the mechanism of enzyme inhibition by the two different types of molecules is completely different. The first ones act as substrate competitors for the binding site, and the second ones, such as AGI-6780, freeze IDH enzymes in an open pre-catalytic conformation, similar to that which is observed in the absence of α-KG or isocitrate and is markedly different from the closed conformation observed when the binding site is occupied by α-KG or isocitrate. Two recent studies have more precisely defined the fine molecular mechanisms through which IDH inhibitors determine the blockade of IDH-mutant enzyme activity.100,101 Deng and colleagues reported that a new selective IDH1 inhibitor acts through interaction with a Mg²⁺ binding residue that is located at the dimer interface. According to these findings, it was suggested that differences in Mg²⁺ binding between WT and mutant enzymes may contribute to the selectivity of inhibitors.100 In the other study, the crystallographic analysis of the structure of another inhibitor (GSK321) bound to mutant IDH1 showed that the inhibitor binds to an allosteric site and freezes the enzyme into an open, catalytically inactive conformation.100 At variance with the other inhibitor, two molecules of the inhibitor GSK 321 bind per enzyme dimer, and this binding was shown to be competitive with α-KG.101 The biologic effect of this inhibitor on primary IDH1-mutant AML blasts was also tested, and showed an initial increase in viable cells, followed by a late reduction in cell viability coupled with an increase in apoptosis, as well as progressive induction of granulocytic differentiation of leukemic cells, as shown by cell morphology and membrane antigen expression. Study of mice xenotransplanted with IDH1-mutant AML cells revealed a decrease in the stem-like leukemic cells and a reduction in the AML blasts in vivo. Finally, as compared to untreated cells, the treated cells showed overall DNA hypomethylation, with consequent up-regulation of genes associated with progenitor growth and differentiation, such as CD38 and MPO.101

Some IDH inhibitors have entered a program of drug development and have already completed testing in phase I clinical trials. The majority of these compounds were developed by the Agios Pharmaceuticals, a publicly-traded American pharmaceutical com-

Fig. 4. Chemical structures of IDH inhibitors. All the reported molecules are active inhibitors, with the exception of GSK990, a structurally inactive inhibitor.
pany focused on developing small-molecule and anticancer compounds that target cancer cell metabolism, which include drugs targeting mutant IDH1 and IDH2 enzymes.

**AG-120**

AG-120 is an IDH1-mutant-specific inhibitor, orally administered and currently being evaluated in multiple clinical trials involving various types of AML patients and IDH1-mutant-positive solid tumors, including glioma, chondrosarcoma and CCA (Table 2) (Fig. 4). Clinical data from an ongoing phase I dose-escalation trial in AML patients with clinically advanced (relapsing/refractory) disease were presented at the 2015 American Society of Hematology (ASH) Annual Meeting and provided evidence that mutant IDH1 is a valuable target in these AML patients. Specifically, it was reported that among 66 patients with relapsing/refractory AMLs bearing the IDH1 mutation, an overall response rate of 36% was observed, along with a complete remission rate of 18%. Among the responders in this study, the median duration of response was 5.6 months. The follow-up of this study will reportedly involve three expansion cohorts, including patients with relapsing/refractory AMLs or with untreated AMLs, and other IDH1-mutation-positive patients with advanced hematologic malignancies. Clinical data from the dose-escalation portion of the ongoing phase I trial of AG-120 in solid tumors (20 gliomas and 35 non-gliomas) were presented at the AACR-NCI-EORTC Meeting in November 2015 and supported a well-tolerated safety profile for this drug and showed signals of clinical activity, sufficient to support additional future evaluation in patients with IDH1-mutant solid tumors. Particularly, 9 low grade and 11 grade III/IV glioma patients were enrolled in the phase I study with AG-120. AG-120 was found to be capable of lowering the levels of 2-HG in the brain. AG-120 administration was also found to be well tolerated, with no dose-limiting toxicity events being observed and with the observed adverse events mostly consisting of low-grade nausea, diarrhea, fatigue, vomiting, headache and peripheral edema. The dose level of 500 mg twice daily was chosen for expansion cohorts. Among the patients with grade II gliomas, 66% responded to treatment, as evidenced by disease stabilization. One of the six patients with grade II gliomas displayed a marked reduction in tumor size. Moreover, 36% of the patients with grade III/IV gliomas responded to treatment, as indicated by disease stabilization. Of the 16 glioma patients evaluable over a longer period of time, 25% were without disease progression at the 6-month mark.

**AG-221**

AG-221 is an orally administered, selective inhibitor of the IDH2-mutant enzyme (Fig. 4). AG-221 has received the designations of ‘orphan drug’ and ‘fast track’ from the United States’ Food and Drug Administration, and is currently under investigation in various types of patients bearing IDH2-mutated cancers, including

### Table 2. IDH inhibitors at various stages of clinical development

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Specificity</th>
<th>Dosing in mg</th>
<th>Clinical Studies</th>
</tr>
</thead>
</table>
| AG-120    | IDH1        | 100–500 (BID), 500–1200 (QD), 500 for phase II studies | NCT02074839 Patients with advanced hematologic malignancies and IDH1 mutations (phase I)  
NCT02073994 Patients with advanced solid tumors and IDH1 mutations (phase I)  
NCT02632708 Safety of AG-120 or AG-221 in combination with induction and consolidation therapies in patients with newly diagnosed acute myeloid leukemia and IDH1 or IDH2 mutations  
NCT02677922 Safety and efficacy of AG-120+azacitidine or AG-221+azacitidine in patients with newly diagnosed acute myeloid leukemia and IDH1 or IDH2 mutations (phase I/II) |
| AG-221    | IDH2        | 30–150 (BID), 50–450 (QD), 100 for phase II studies | NCT1915498 Patients with advanced hematologic malignancies and IDH2 mutations (phase I/II)  
NCT02273739 Patients with advanced solid tumors, including gliomas and angioimmunoblastic T-lymphoma, and IDH2 mutations (phase I/II)  
NCT02577406 Efficacy and safety of AG-221 versus conventional care regimens in older patients with late-stage acute myeloid leukemia and IDH2 mutations (phase I/II)  
NCT02632708 Safety of AG-120 or AG-221 in combination with induction and consolidation therapies in patients with newly diagnosed acute myeloid leukemia and IDH1 or IDH2 mutations  
NCT02677922 Safety and efficacy of AG-120+azacitidine or AG-221+azacitidine in patients with newly diagnosed acute myeloid leukemia and IDH1 or IDH2 mutations (phase I/II) |
| AG-881    | IDH1/IDH2   | 5–100 (QD)   | NCT02492737 Patients with advanced hematologic malignancies and IDH1 or IDH2 mutation (phase I)  
NCT02481154 Patients with advanced solid tumors, including gliomas, and IDH1 and/or IDH2 mutation (phase I) |
| IDH305    | IDH1        | 5–100 (QD)   | NCT02381886 Patients with advanced malignancies that harbor IDH1 mutations (phase I)  
NCT02826642 A dose-finding study of IDH305 with standard-of-care in IDH1 mutant acute myeloid leukemia |

Abbreviations: QD: once per day; BID: twice per day.
relapsing/refractory AMLs and older relapsing/refractory AML patients (comprising a comparative study with conventional standard regimens, as frontline therapy of AML patients in combination with chemotherapy or 5-azacytidine). Pre-clinical studies have supported a robust antitumor activity of AG-221, documented in primary AML blasts carrying the IDH2-R140Q mutation in xenograft models; specifically, administration of the drug was shown to confer a survival advantage and to induce differentiation of the grafted leukemic cells in vivo.105

Recent preliminary results of the first human phase I/II dose-escalation study with AG-221 (Table 2) have been reported.105 Among the 128 cases of relapsing/refractory AMLs studied, 41% had objective responses, with a median response duration of 6.0 months. The response rates were found to be independent of the number of previous therapeutic regimens and of the molecular type of IDH2 mutation (either R140Q or R172K). Finally, 8 of the treated patients have been reported as ultimately requiring bone marrow transplantation.105

**AG-811**

The Agios Company also developed the AG-811 compound, an orally administered inhibitor exhibiting inhibitory activity against both IDH1 and IDH2-mutated enzymes. In preclinical studies, this inhibitor displayed the important property of fully penetrating the blood:brain barrier, thus offering the potential to treat glioma patients. Furthermore, this drug could represent a second-generation inhibitor for AG-120 and AG-221 in IDH-mutant tumors. Two types of clinical studies have been planned for this drug, one in patients with IDH-mutant solid tumors and one in patients with advanced hematologic malignancies who have progressed on a prior IDH inhibitor therapy (Table 2).

**IDH 305**

Another IDH1 inhibitor under clinical evaluation is IDH 305. IDH 305 specifically inhibits the IDH1-R132 mutant form. This drug is currently under evaluation in phase I/II clinical studies focusing on patients with advanced hematologic and solid IDH1-mutant tumors (Table 2).

**Alternative therapeutic strategies**

Some recent studies have shown that, in addition to the direct targeting of IDH-mutant enzymes, other biochemical pathways can be efficiently targeted in these leukemic cells to obtain a therapeutically significant effect. In this context, the study carried out by Chan and colleagues is particularly interesting. That study exemplified a large-scale RNA interference (RNAi) screen to identify genes that are synthetic lethal to IDH1-R132H; ultimately, the screen identified the Bcl-2 gene.106 In line with these observations, both IDH1- and IDH2-mutant AML cells were found to be more sensitive to BCL-2 targeting than were the non IDH-mutant AML cells upon treatment with the small molecule inhibitor ABT-199. This BCL-2 inhibitor induced apoptosis of the leukemic cells. Collectively, the findings from that study indicated that the IDH1/2 mutation status identifies a subgroup of AMLs that are responsive to pharmacologic BCL-2 inhibition.106

Very interestingly, in a phase 1 clinical trial, treatment with BCL-2 inhibitor ABT-199 achieved complete responses in 5 of 32 AML patients, the majority of whom had relapsed/refractory leukemic disease; three of those 5 complete responders were IDH-mutant AMLs.107 In addition, 3 of 11 AML patients with IDH mutations achieved a complete response following the ABT-199 treatment.107 Obviously, the number of treated patients is too low to support any conclusion about the clinical efficacy of BCL-2 inhibitors in IDH-mutant AMLs.

The studies carried out on IDH mutant AMLs are paradigmatic for demonstrating the key role of epigenetic modifiers on leukemia development and the therapeutic value of their targeting. In this context, particularly interesting and reminiscent of the observations made for IDH-mutant leukemic cells, are the results reported in a recent study showing that loss-of-function DNMT3A mutations can determine overexpression of the lysine methyltransferase DOT1L.108 Pharmacological inhibition of the DOT1L inhibitor EPZ5676 displayed antitumor activity in vivo, as evidenced in a nude rat xenograft model of DNMT3A-mutant AML. Specifically, the DOT1L inhibition elicited an antileukemic effect against primary DNMT3A-mutant AML cells, reducing their clonogenic capacity and inducing their differentiation.108

Tateishi and colleagues have identified an alternative strategy to metabolically target IDH-mutant tumor cells.109 The initial analysis involved the effects of deregulated Myc that had been observed in many tumors, regarding the metabolic state; the features examined included increased glycolytic rate and glutaminolysis to meet the increased biosynthetic demand of cancer cells. This altered cell metabolism was proposed to render Myc-driven cancers particularly sensitive to nutrient deprivation.109 Using a panel of patient-derived glioblastoma tumorsphere lines, the researchers showed that glycolytic inhibition using small molecule inhibitors of the NAD+ salvage enzyme nicotinamide phosphoribosyl-transferase (NAMPT) may represent a powerful strategy to inhibit Myc-driven cancers.110 Given these observations, Tateishi and colleagues subsequently compared the metabolic profiles of IDH1-mutant glioma tumor initiating cells without and with IDH inhibition to identify potential metabolic vulnerabilities.111 The results demonstrated that IDH1-mutant cancer cells are extremely vulnerable to depletion of the coenzyme NAD+, a phenomenon that was likely due to the pronounced depletion of NAD+ levels observed in these cells and due to the down-regulation of the inhibition of the NAD+ salvage pathway enzyme NAMPT.111 NAD+ depletion was also shown to activate an autophagic process, resulting in cytotoxicity.111 Since NAMPT inhibitors have entered clinical development, these findings have the potential perspective for rapid translation in IDH-mutant neoplasias.112

**Molecular imaging of IDH-mutant tumors**

The unique features of glucose, glutamine and lipid metabolism identified in IDH-mutant tumors can be exploited for molecular imaging of these tumors. This approach has important implications at the diagnostic level and represents a valuable tool for monitoring response to drug treatments. Furthermore, this tool has proven useful in preclinical studies of drug discovery, when applied to suitable animal models.

The molecular imaging of IDH-mutant tumors was investigated for human gliomas. Unfortunately, the markedly increased concentration of 2-HG exceeds the sensitivity threshold for in vivo magnetic resonance spectroscopy.113 Numerous studies have shown the feasibility of single voxel or single slice magnetic resonance spectroscopy (MRS) in vivo for detection of 2-HG in IDH-mutant gliomas of human patients.114–116 However, the in vivo detection of 2-HG by conventional MRS is challenging, and particular editing spectroscopic methods are required to unambiguously distinguish
the true 2-HG signal from spurious overlapping signals caused by metabolites with similar chemical structures. Nonetheless, the 2-HG imaging approach has diagnostic/prognostic value for prediction of treatment outcome and for longitudinal monitoring of treatment response. The development of more sophisticated MRS techniques, such as three-dimensional (3D) MRS imaging sequence (MRSI), allow for selective editing of 2-HG, with increased temporal stability and spatial coverage. This technique was demonstrated as useful for the careful monitoring of response to standard therapy of IDH-mutant gliomas. Other studies have confirmed that 2-HG-MRS can be linked with routine MR imaging to provide a quantitative measurement of 2-HG content in gliomas, which represents a useful biomarker to monitor the abundance of noninvasive IDH-mutant tumor cells during glioma treatment. Interestingly, a recent analysis of the volumetric relationship between 2-HG-MRSI and standard MR imaging showed that, in about half of glioma patients, the 2-HG volumetric assessment of tumor burden is more extensive than that of the standard MR imaging volume, as assessed by fluid-attenuated inversion recovery (FLAIR) hyperintensity. The standard MRS technology commonly used in clinical studies implies a high-resolution magic angle spinning proton magnetic resonance spectroscopy (‘H-MRS) at magnetic field strengths of 3T. Using this technique, the selective detection of 2-HG-related signals is challenging because of the overlapping signals that are generated by glutamine, glutamate, glutathione and γ-aminobutyric acid. This problem can be avoided, however, by using ultrahigh magnetic fields (UHF; ≥7T) because the in vivo ‘H-MRS detection of 2-HG and other metabolites in this condition gains in signal-to-noise ratio and in spectral resolution, thus allowing the detection of small changes in 2-HG levels from small volumes of interest and with a higher specificity compared to techniques with the 3T magnetic field. Using this improved technique, it was demonstrated that IDH2-mutant gliomas produced more 2-HG than IDH1-mutant tumors. Importantly, this technology offers the opportunity to quantify the neurochemical profiles of at least eight metabolites, including 2-HG, glutamate, glutamine, lactate and glutathione, in both tumoral and normal tissues. Other studies have confirmed the efficacy of 7T MRS for in vivo detection of 2-HG in brain tumors, with discrimination of this metabolite from glutamine, glutamate and GABA.

Finally, the in vivo imaging of IDH-mutant tumors may have a fundamental impact on the discovery of new drugs with inhibitory activity against these tumors. Indeed, in vitro and in vivo monitoring of 2-HG levels have led to the discovery Zaprinast, a phosphodiesterase 5 inhibitor, as a glutaminase inhibitor acting as an efficacious modulator of 2-HG production. For experimental studies, bioluminescence techniques on tumor biopsies allowed for the determination of 2-HG, ATP, glucose, pyruvate, and lactate by quantitative imaging. Finally, this technique allows for evaluation of the metabolic profile of individual tumors and the potential effect of some inhibitory drugs.

Conclusions

In conclusion, the studies carried out in the last few years have shown that, while normal IDH enzymes catalyze the oxidative decarboxylation of isocitric acid to produce α-KG, the mutant IDH1 and IDH2 enzymes lose this function and catalyze a new reaction, namely the reduction of α-KG to D-2-HG. This neomorphic function leads to the generation of markedly increased levels of this anomalous metabolite (i.e. D-2-HG), which is present only in trace amounts in normal cells. D-2-HG was found to inhibit α-KG-dependent KDMs and the TET family of 5-methylcytosine hydroxylases, with consequent hypermethylation of histones and DNA. These molecular events are responsible for the blockade of cell differentiation observed in IDH-mutant tumors. Studies of the molecular evolution of IDH-mutant AMLs and gliomas strongly support the view that IDH mutations are early driver events promoting the initial steps of tumor development and are fully maintained during tumor progression, therefore representing ideal targets for therapeutic purposes.

These observations have provided evidence that strongly supports the notion that IDH mutations will be effective drug targets for intervention. A number of potent and selective inhibitors of mutant IDH1 and IDH2 have been synthesized and characterized in detail. Some of these inhibitors have entered active programs of clinical development and are currently under investigation in phase I/II studies on IDH-mutant tumors, including AMLs, gliomas, CCAs and chondrosarcomas. Two of these inhibitors, in particular, AG-221 and AG-120, have exhibited promising clinical pharmacokinetic, safety and efficacy profiles.

Conflict of interest

The authors have no conflict of interests related to this publication.

Author contributions

Preparation of the manuscript including Tables and Figures (EP, GC, UT).

References

[10] Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADP+-dependent reductive carbonyl...


Pelosi E. et al: Isocitrate Dehydrogenase Mutations in Human Cancers